Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis

Author:

Abolhassani-Chimeh Reihaneh1,Akkerman Onno W.23ORCID,Saktiawati Antonia M. I.45,Punt Nieko C.16,Bolhuis Mathieu S.1,Subronto Yanri W.4,Sumardi 4,van der Werf Tjip S.27,Kosterink Jos G. W.18,Alffenaar Jan-Willem C.191011ORCID,Sturkenboom Marieke G. G.1ORCID

Affiliation:

1. University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands

2. University Medical Center Groningen, Department of Pulmonary Diseases, University of Groningen, Groningen, the Netherlands

3. University Medical Center Groningen, Tuberculosis Center Beatrixoord, University of Groningen, Haren, the Netherlands

4. Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

5. Center for Tropical Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia

6. Medimatics, Maastricht, the Netherlands

7. University Medical Center Groningen, Department of Internal Medicine/Infectious Diseases, University of Groningen, Groningen, the Netherlands

8. Pharmacotherapy, Epidemiology and Economy, Groningen Research Institute of Pharmacy, University of Groningen, Groningen, the Netherlands

9. Faculty of Medicine and Health, School of Pharmacy, University of Sydney, Sydney, New South Wales, Australia

10. Westmead Hospital, Westmead, New South Wales, Australia

11. Marie Bashir Institute of Infectious Diseases and Biosecurity, University of Sydney, Sydney, New South Wales, Australia

Abstract

Pyrazinamide is one of the first-line antituberculosis drugs. The efficacy of pyrazinamide is associated with the ratio of 24-h area under the concentration–time curve (AUC 24 ) to MIC.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference48 articles.

1. World Health Organization (WHO). 2021. Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland.

2. World Health Organization. 2017. Guidelines for the treatment of drug-susceptible tuberculosis and patient care. World Health Organization, Geneva, Switzerland.

3. The curious characteristics of pyrazinamide: a review;Zhang Y;Int J Tuber Lung Dis,2003

4. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy;British Thoracic Association;Am Rev Respir Dis,1982

5. The Role of Pyrazinamide in Tuberculosis Chemotherapy

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3